Galderma Group AG GALDY

Health CarePersonal & Household Products & ServicesSwitzerland

Last close 46.58 USD on Nov 2, 2026, +12.6% year to date

Quant rating

Quant rating B Rank 80 of 211 in Health Care

Growth D 187 of 211
Valuation B 72 of 211
Quality C 123 of 211
Revisions A 30 of 211
Momentum A 26 of 211

Wall Street consensus Buy (1.88)Average target 253.92 USD +445.1%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 55.2B
Enterprise value: 57.1B
52-week range: 35.53 – 47.00
3-year range: 15.51 – 47.00
Dividend yield: 0.19%
Beta (5 years): –
Shares outstanding: 238M
Next earnings: Oct 23, 2026

About the company

Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.

Growth and profitability fiscal year ends December 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	5,241	4,440	4,116	3,824	3,445	–
Revenue growth	18.0%	7.9%	7.7%	11.0%	–	–
EPS (basic, normalized)	3.69	2.09	–	–	–	–
EPS growth	76.6%	–	–	–	–	–
Gross margin	69.0%	69.5%	70.1%	68.8%	70.0%	69.5%
Net margin	11.7%	5.2%	−1.4%	−2.5%	−2.4%	2.1%
ROE	7.7%	3.5%	−1.2%	−2.1%	–	2.0%

Balance sheet, last quarter
Cash & short-term investments (mil)	–
Current ratio	–
Long-term debt (mil)	–
Net debt (mil)	–
Total equity (mil)	–
Net debt / equity	–
Net debt / EBITDA	–

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	5,241	+18.0%	10.9x	1,211	+19.7%	47.1x	3.69	+76.6%	12.6x
2026	6,468	+23.4%	8.8x	1,678	+38.6%	34.0x	4.86	+31.6%	9.6x
2027	7,707	+19.2%	7.4x	2,182	+30.0%	26.2x	6.64	+36.7%	7.0x
2028	8,943	+16.0%	6.4x	2,746	+25.8%	20.8x	8.67	+30.6%	5.4x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	6,468	+1.1%	+1.4%	+2.5%	4.86	+1.0%	+1.9%	+5.6%
2027	7,707	+2.5%	+3.0%	+4.3%	6.64	+0.8%	+2.2%	+5.4%
2028	8,943	+3.1%	+3.4%	+5.0%	8.67	+1.4%	+2.4%	+5.0%

Earnings surprises

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	FQ-9	Jun 2024	FQ-7	FQ-6	FQ-5	FQ-4	FQ-3	FQ-2	FQ-1	FQ0
Sales reported (mil)	–	–	1,068	1,151	1,129	1,320	1,288	1,470	1,473	1,661
Sales mean (mil)	–	–	1,091	1,169	1,124	1,266	1,242	1,423	1,453	1,598
Surprise	–	–	−2.1%	−1.5%	+0.4%	+4.3%	+3.7%	+3.3%	+1.4%	+3.9%
EPS reported	–	0.55	–	–	–	–	–	–	–	–
EPS mean	–	1.12	–	0.95	–	–	–	–	–	–
Surprise	–	−50.9%	–	–	–	–	–	–	–	–

Peer comparison Personal & Household Products & Services

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
GALDY Galderma Group AG	55.2B	–	11.7%	6.64x	9.6x	7.0x	34.0x	26.2x
CL Colgate-Palmolive Company	77.4B	1.30x	10.5%	268.92x	24.9x	23.8x	16.4x	15.7x
RBGLY Reckitt Benckiser Group PLC	47.3B	–	22.5%	6.30x	16.6x	16.1x	12.2x	11.7x
EL Estee Lauder Companies Inc	38.0B	1.63x	1.6%	9.96x	31.5x	26.0x	14.6x	12.8x
KVUE Kenvue Inc.	37.1B	2.09x	9.7%	3.51x	16.4x	15.6x	12.1x	11.4x
KMB Kimberly-Clark Corporation	36.0B	1.61x	9.3%	20.57x	14.6x	14.6x	11.7x	11.0x
Mean		1.66x	10.9%	52.65x	18.9x	17.2x	16.8x	14.8x
Median		1.62x	10.1%	8.30x	16.5x	15.8x	13.4x	12.3x

Technical analysis

1M+20.2%
3M+6.8%
1Y+26.2%
3Y+185.3%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Galderma Group AG, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	5,241	4,440	4,116	3,824	3,445	–
Cost of revenue	1,627	1,355	1,232	1,194	1,034	–
Gross profit	3,614	3,085	2,885	2,630	2,411	–
Selling, general & administrative expenses	2,196	1,920	1,759	1,699	1,535	–
Research & development	245	260	287	316	343	–
Depreciation/amortization	37.0	–	–	–	–	–
Interest expense (income), operating	19.0	4.0	30.9	17.7	9.3	–
Unusual expense (income)	39.0	26.0	41.2	72.1	76.1	–
Other operating expenses	249	230	231	214	184	–
Operating income	829	645	536	311	264	–
Net interest income (expense)	−172	−341	−553	−374	−269	–
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	−19.0	6.0	28.6	10.6	−74.8	–
Net income before taxes	638	310	11.0	−51.9	−79.7	–
Provision for taxes	26.0	79.0	68.1	45.0	4.6	–
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	612	231	−57.1	−96.9	−84.3	–
Extraordinary items	–	–	0	−1.6	−72.0	–
Net income	612	231	−57.1	−98.5	−156	–
EBIT, normalized	887	675	608	401	350	–
EBITDA, normalized	1,211	968	884	679	603	–
Basic EPS, normalized	3.69	2.09	–	–	–	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Galderma Group AG, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	780	457	368	234	287	–
Receivables	1,062	905	766	791	732	–
Total inventory	525	403	420	442	347	–
Prepaid expenses	66.0	56.0	56.0	35.1	36.5	–
Other current assets	4.0	22.0	7.1	4.5	115	–
Total current assets	2,437	1,843	1,616	1,507	1,517	–
Property, plant & equipment	744	577	529	401	342	–
Goodwill	5,129	5,129	5,129	5,129	5,140	–
Intangibles	4,639	4,829	4,923	5,100	5,282	–
Long-term investments	3.0	1.0	10.3	8.8	7.3	–
Note receivable	–	–	–	–	–	–
Other long-term assets	441	238	264	270	283	–
Total assets	13,393	12,617	12,471	12,415	12,572	–
Liabilities
Accounts payable	799	571	557	602	502	–
Payable/accrued	–	–	–	–	–	–
Accrued expenses	715	586	530	534	506	–
Short-term debt	1.0	3.0	4.1	0	0	–
Current portion of long-term debt	38.0	30.0	55.7	412	427	–
Other current liabilities	502	338	424	411	421	–
Total current liabilities	2,055	1,528	1,571	1,961	1,857	–
Long-term debt	2,689	2,723	4,846	5,245	5,261	–
Minority interest	–	–	–	–	–	–
Other liabilities	500	576	686	740	906	–
Total liabilities	5,244	4,827	7,102	7,946	8,024	–
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	3.0	3.0	6.3	5,248	5,248	–
Additional paid-in capital	2,089	2,133	6,253	–	–	–
Retained earnings (accumulated deficit)	6,411	5,724	−858	−771	−719	–
Treasury stock	−378	−15.0	–	–	–	–
Other equity	24.0	−55.0	−31.8	−7.8	19.7	–
Total equity	8,149	7,790	5,369	4,469	4,548	–
Total liabilities & shareholders' equity	13,393	12,617	12,471	12,415	12,572	–

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Galderma Group AG, fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	613	231	−57.2	−98.5	−156	–
Depreciation, depletion & amortization	323	293	276	278	253	–
Deferred taxes	–	–	–	–	–	–
Non-cash items	312	477	594	423	428	–
Changes in working capital	−63.0	−513	−648	−491	−329	–
Cash from operations	1,185	488	165	111	196	–
Investing activities
Capital expenditures	−154	−275	−153	−160	−128	–
Other investing cash flows	0	−51.0	−20.9	93.0	−395	–
Cash from investing	−154	−326	−174	−66.5	−523	–
Financing activities
Financing cash flow items	−31.0	−33.0	0	−7.3	−10.7	–
Cash dividends paid	−41.0	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−656	−25.0	142	−72.1	317	–
Cash from financing	−728	−58.0	142	−79.4	306	–
Foreign exchange effects	20.0	−14.0	0.3	−24.9	−16.5	–
Net change in cash	323	90.0	134	−59.5	−37.1	–
Free cash flow	1,031	213	12.6	−48.2	67.7	–

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.